Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar

被引：0
|
作者：
Mahmmod, S. [1 ]
Schultheiss, J. P. D. [1 ]
Tan, A. C. I. T. L. [2 ]
Lutgens, M. W. M. D. [3 ]
Gilissen, L. P. L. [4 ]
Mahmmod, N. [5 ]
van der Meulen-de Jong, A. E. [6 ]
Dijkstra, G. [7 ]
van Bodegraven, A. A. [8 ]
Oldenburg, B. [1 ]
Fidder, H. H. [1 ]
机构：
[1] UMC Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands
[2] Canisius Wilhelmina Ziekenhuis, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Elisabeth TweeSteden Ziekenhuis, Dept Gastroenterol & Hepatol, Tilburg, Netherlands
[4] Catharina Hosp, Dept Gastroenterol & Hepatol, Eindhoven, Netherlands
[5] St Antonius Hosp, Dept Gastroenterol & Hepatol, Nieuwegein, Netherlands
[6] Leiden UMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[7] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[8] Zuyderland Ziekenhuis, Dept Gastroenterol & Hepatol, Sittard, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P326
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [21] Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial
    Jorgensen, K. K.
    Goll, G. L.
    Sexton, J.
    Olsen, I. C.
    Bolstad, N.
    Lundin, K. E.
    Berset, I. P.
    Haavardsholm, E. A.
    Mork, C.
    Kvien, T. K.
    Jahnsen, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S348 - S349
  • [22] Comparative effectiveness of the biosimilar CT-P13
    Yoo, Dae Hyun
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (08) : 693 - 712
  • [23] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
    Park, Won
    Miranda, Pedro
    Brzosko, Marek
    Wiland, Piotr
    Gutierrez-Urena, Sergio
    Mikazane, Helena
    Lee, Yeon-Ah
    Smiyan, Svitlana
    Lim, Mie-Jin
    Kadinov, Vladimir
    Abud-Mendoza, Carlos
    Son, YoungKi
    Yoo, Dae-Hyun
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3326 - 3326
  • [24] Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
    Bronswijk, Michiel
    Moens, Annick
    Lenfant, Matthias
    Tops, Sophie
    Compernolle, Griet
    Van Assche, Gert
    Vermeire, Severine
    Gils, Ann
    Ferrante, Marc
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (04) : 628 - 634
  • [25] Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect
    Germain, Vincent
    Scherlinger, Marc
    Barnetche, Thomas
    Schaeverbeke, Thierry
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01)
  • [26] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    Yoo, Dae Hyun
    Prodanovic, Nenad
    Jaworski, Janusz
    Miranda, Pedro
    Ramiterre, Edgar
    Lanzon, Allan
    Baranauskaite, Asta
    Wiland, Piotr
    Abud-Mendoza, Carlos
    Oparanov, Boycho
    Smiyan, Svitlana
    Kim, HoUng
    Lee, Sang Joon
    Kim, SuYeon
    Park, Won
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
  • [27] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
    Jorgensen, Kristin K.
    Olsen, Inge C.
    Goll, Guro L.
    Lorentzen, Merete
    Bolstad, Nils
    Haavardsholm, Espen A.
    Lundin, Knut E. A.
    Mork, Cato
    Jahnsen, Jorgen
    Kvien, Tore K.
    LANCET, 2017, 389 (10086): : 2304 - 2316
  • [28] Biosimilar CT-P13 comparable to infliximab in active RA
    Nature Reviews Rheumatology, 2013, 9 (7) : 382 - 382
  • [29] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [30] CT-P13 biosimilar is non-inferior to infliximab
    Dickson I.
    Nature Reviews Gastroenterology & Hepatology, 2019, 16 (6) : 326 - 326
12345